Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 283

1.

Psychiatric manifestations in Wilson's disease: possibilities and difficulties for treatment.

Litwin T, Dusek P, Szafrański T, Dzieżyc K, Członkowska A, Rybakowski JK.

Ther Adv Psychopharmacol. 2018 Jul;8(7):199-211. doi: 10.1177/2045125318759461. Epub 2018 Mar 6. Review.

2.

Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial.

Barnes TRE, Leeson V, Paton C, Marston L, Osborn DP, Kumar R, Keown P, Zafar R, Iqbal K, Singh V, Fridrich P, Fitzgerald Z, Bagalkote H, Haddad PM, Husni M, Amos T.

Ther Adv Psychopharmacol. 2018 Jul;8(7):185-197. doi: 10.1177/2045125318762365. Epub 2018 Mar 8.

3.
4.

Switching and augmentation strategies for antipsychotic medications in acute-phase schizophrenia: latest evidence and place in therapy.

Hatta K, Sugiyama N, Ito H.

Ther Adv Psychopharmacol. 2018 Jun;8(6):173-183. doi: 10.1177/2045125318754472. Epub 2018 Jan 29. Review.

5.

Naming the drugs we use: neuroscience-based nomenclature, a helpful innovation.

Wilson S.

Ther Adv Psychopharmacol. 2018 Jun;8(6):171-172. doi: 10.1177/2045125318762065. Epub 2018 Mar 6. No abstract available.

6.

Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation.

Fluyau D, Revadigar N, Manobianco BE.

Ther Adv Psychopharmacol. 2018 May;8(5):147-168. doi: 10.1177/2045125317753340. Epub 2018 Feb 9. Review.

7.

Effectiveness of paliperidone long-acting injection in clinical practice.

Deslandes PN, Ward EH, Norris K, Sewell RD.

Ther Adv Psychopharmacol. 2018 May;8(5):139-145. doi: 10.1177/2045125317753332. Epub 2018 Jan 17.

8.

The antipsychotic landscape: dopamine and beyond.

Morrison PD, Murray RM.

Ther Adv Psychopharmacol. 2018 Apr;8(4):127-135. doi: 10.1177/2045125317752915. Epub 2018 Jan 23. Review.

9.

A prospective year-long follow-up of lurasidone use in clinical practice: factors predicting treatment persistence.

Osborne IJ, Mace S, Taylor D.

Ther Adv Psychopharmacol. 2018 Apr;8(4):117-125. doi: 10.1177/2045125317749740. Epub 2018 Jan 7.

10.

Benzodiazepine prescription in Ontario residents aged 65 and over: a population-based study from 1998 to 2013.

Davies SJC, Jacob B, Rudoler D, Zaheer J, de Oliveira C, Kurdyak P.

Ther Adv Psychopharmacol. 2018 Mar;8(3):99-114. doi: 10.1177/2045125317743651. Epub 2017 Dec 5.

11.

Alternatives to ketamine in depression: state-of-the-art and future perspectives.

Jelen LA, King S, Stone JM.

Ther Adv Psychopharmacol. 2018 Mar;8(3):95-98. doi: 10.1177/2045125317749456. Epub 2017 Dec 18. No abstract available.

12.

Neuromodulation for the treatment of eating disorders and obesity.

Lee DJ, Elias GJB, Lozano AM.

Ther Adv Psychopharmacol. 2018 Feb;8(2):73-92. doi: 10.1177/2045125317743435. Epub 2017 Dec 8. Review.

13.

When the drugs don't work: treatment-resistant schizophrenia, serotonin and serendipity.

Lowe P, Krivoy A, Porffy L, Henriksdottir E, Eromona W, Shergill SS.

Ther Adv Psychopharmacol. 2018 Jan;8(1):63-70. doi: 10.1177/2045125317737003. Epub 2017 Nov 2.

14.

Acetylcholinesterase inhibitors in treatment-resistant psychotic depression.

Smart C, McAllister-Williams H, Cousins DA.

Ther Adv Psychopharmacol. 2018 Jan;8(1):59-61. doi: 10.1177/2045125317718810. Epub 2017 Jul 10.

15.

The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder.

Clevenger SS, Malhotra D, Dang J, Vanle B, IsHak WW.

Ther Adv Psychopharmacol. 2018 Jan;8(1):49-58. doi: 10.1177/2045125317737264. Epub 2017 Nov 1. Review.

16.

Frontotemporal dementia: latest evidence and clinical implications.

Young JJ, Lavakumar M, Tampi D, Balachandran S, Tampi RR.

Ther Adv Psychopharmacol. 2018 Jan;8(1):33-48. doi: 10.1177/2045125317739818. Epub 2017 Nov 10. Review.

17.

Treatment of adult ADHD: a clinical perspective.

Geffen J, Forster K.

Ther Adv Psychopharmacol. 2018 Jan;8(1):25-32. doi: 10.1177/2045125317734977. Epub 2017 Oct 25. Review.

18.

Assessment and management of sexual dysfunction in the context of depression.

Chokka PR, Hankey JR.

Ther Adv Psychopharmacol. 2018 Jan;8(1):13-23. doi: 10.1177/2045125317720642. Epub 2017 Jul 31. Review.

19.

Clozapine discontinuation in early schizophrenia: a retrospective case note review of patients under an early intervention service.

Shaker A, Jones R.

Ther Adv Psychopharmacol. 2018 Jan;8(1):3-11. doi: 10.1177/2045125317741449. Epub 2017 Nov 19.

20.

Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature.

Meid AD, Bighelli I, Mächler S, Mikus G, Carrà G, Castellazzi M, Lucii C, Martinotti G, Nosè M, Ostuzzi G, Barbui C, Haefeli WE.

Ther Adv Psychopharmacol. 2017 Dec;7(12):251-264. doi: 10.1177/2045125317721662. Epub 2017 Aug 28.

Supplemental Content

Loading ...
Support Center